{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:19:36Z","timestamp":1788740376466,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ejps.2021.105940","type":"journal-article","created":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T11:57:17Z","timestamp":1626091037000},"page":"105940","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Clinical investigation of the biopharmaceutical characteristics of nifurtimox tablets \u2013 Implications for quality control and application"],"prefix":"10.1016","volume":"166","author":[{"given":"Heino","family":"Stass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Just","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Weimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Ince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Willmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethel","family":"Feleder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Yerino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"M\u00fcnster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2021.105940_bib0001","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008912","article-title":"Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO)","volume":"15","author":"Altcheh","year":"2021","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ejps.2021.105940_bib0002","first-page":"154","article-title":"Chagas disease: current perspectives on a forgotten disease","volume":"81","author":"\u00c1lvarez-Hern\u00e1ndez","year":"2018","journal-title":"Rev. Med. Hosp. Gen. M\u00e9x."},{"key":"10.1016\/j.ejps.2021.105940_bib0003","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1056\/NEJMra1410150","article-title":"Chagas Diseasedisease","volume":"373","author":"Bern","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2021.105940_bib0004","unstructured":"Centers for Disease Control and Prevention, 2019. Parasites \u2013 American trypanosomiasis (also known as Chagas disease). Available from: https:\/\/www.cdc.gov\/parasites\/chagas\/index.html."},{"key":"10.1016\/j.ejps.2021.105940_bib0005","first-page":"1617","article-title":"Investigations on the pharmacokinetics of nifurtimox- 35 S in the rat and dog","volume":"22","author":"Duhm","year":"1972","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.ejps.2021.105940_bib0006","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/IPC.0000000000000512","article-title":"Addressing the Challenges challenges of Chagas Diseasedisease","volume":"25","author":"Edwards","year":"2017","journal-title":"Infect. Dis. Clin. Pract. (Baltim Md)."},{"key":"10.1016\/j.ejps.2021.105940_bib0007","unstructured":"European Medicines Agency., 2000. ICH Topic Q 6 A \u2013 Not for Guidance Specifications: Test test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical chemical Substances (CPMP\/ICH\/367\/96). Decision Tree #7: SETTING ACCEPTANCE CRITERIA FOR DRUG PRODUCT DISSOLUTION. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-q-6-test-procedures-acceptance-criteria-new-drug-substances-new-drug-products-chemical_en.pdf."},{"key":"10.1016\/j.ejps.2021.105940_bib0008","unstructured":"European Medicines Agency., 2010. Guideline on the investigation of bioequivalence \u2013 Revision revision 1. August 01. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf."},{"key":"10.1016\/j.ejps.2021.105940_bib0009","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/cid\/ciw477","article-title":"Safety profile of nifurtimox for treatment of Chagas disease in the United States","volume":"63","author":"Forsyth","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejps.2021.105940_bib0010","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/adc.2008.157297","article-title":"Is use of nifurtimox for the treatment of Chagas disease compatible with breast feeding? A population pharmacokinetics analysis","volume":"95","author":"Garcia-Bournissen","year":"2010","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.ejps.2021.105940_bib0011","article-title":"Nutritive value of foods. US Department of Agriculture, Agricultural Research Service","volume":"72","author":"Gebhardt","year":"2002"},{"key":"10.1016\/j.ejps.2021.105940_bib0012","doi-asserted-by":"crossref","first-page":"13088","DOI":"10.1074\/jbc.M111.230847","article-title":"Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites","volume":"286","author":"Hall","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejps.2021.105940_bib0013","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijid.2019.07.020","article-title":"Chagas disease in the Bolivian Chaco: Persistent persistent transmission indicated by childhood seroscreening study","volume":"86","author":"Hopkins","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.ejps.2021.105940_bib0014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006896","article-title":"A decade of vector control activities: Progress progress and limitations of Chagas disease prevention in a region of Guatemala with persistent Triatoma dimidiata infestation","volume":"12","author":"Juarez","year":"2018","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ejps.2021.105940_bib0015","first-page":"1613","article-title":"Quantitative determination of nifurtimox in body fluids of rat, dog and man","volume":"22","author":"Medenwald","year":"1972","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.ejps.2021.105940_bib0016","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40506-018-0170-z","article-title":"Treatment of Chagas disease in the United States","volume":"10","author":"Meymandi","year":"2018","journal-title":"Curr. Treat. Options Infect. Dis."},{"key":"10.1016\/j.ejps.2021.105940_bib0017","first-page":"64","article-title":"Mathematical comparison of curves with an emphasis on in vitro dissolution profiles","volume":"20","author":"Moore","year":"1996","journal-title":"Pharm. Tech."},{"key":"10.1016\/j.ejps.2021.105940_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007647","article-title":"Negligible exposure to nifurtimox through breast milk during maternal treatment for Chagas disease","volume":"13","author":"Moroni","year":"2019","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ejps.2021.105940_bib0019","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/jphp.12957","article-title":"Food for thought: formulating away the food effect\u2014a PEARRL review","volume":"71","author":"O'Shea","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2021.105940_bib0020","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.4269\/ajtmh.15-0256","article-title":"Safety profile of nifurtimox and treatment interruption for chronic Chagas disease in Colombian adults","volume":"93","author":"Olivera","year":"2015","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ejps.2021.105940_bib9028","unstructured":"Paulos, C., Paredes, J., Vasquez, I., Thambo, S., Arancibia, A., Gonzalez-Martin, G., 1989. Pharmacokinetics of a nitrofuran compound, nifurtimox, in healthy volunteers. Int. J. Clin. Pharmacol. Ther. Toxicol. 27, 454-457."},{"key":"10.1016\/j.ejps.2021.105940_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005783","article-title":"Towards Chagas disease elimination: Neonatal neonatal screening for congenital transmission in rural communities","volume":"11","author":"Pennington","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ejps.2021.105940_bib0023","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/jphp.12999","article-title":"The impact of food intake on the luminal environment and performance of oral drug products with a view to in vitro and in silico simulations: a PEARRL review","volume":"71","author":"Pentafragka","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2021.105940_bib0024","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/S0140-6736(10)60061-X","article-title":"Chagas disease","volume":"375","author":"Rassi","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejps.2021.105940_bib0025","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1590\/0074-02760160407","article-title":"Chagas disease: national survey of seroprevalence in children under five years of age conducted in 2008","volume":"112","author":"Russomando","year":"2017","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.ejps.2021.105940_bib0026","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/cpdd.871","article-title":"Biopharmaceutical characteristics of nifurtimox tablets for age- and body weight-adjusted dosing in patients with Chagas disease","volume":"10","author":"Stass","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.ejps.2021.105940_bib0027","unstructured":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), 2021. M9 Biopharmaceutics classification system-based biowaivers \u2013 guidance for industry. Available from: https:\/\/www.fda.gov\/media\/148472\/download."},{"key":"10.1016\/j.ejps.2021.105940_bib0028","unstructured":"The International Pharmacopoeia \u20139th Edition., 2019. Nifurtimox. Available from: https:\/\/apps.who.int\/phint\/pdf\/b\/6.1.253.Nifurtimox-(Nifurtimoxum).pdf."},{"key":"10.1016\/j.ejps.2021.105940_bib0029","series-title":"Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms","year":"1997"},{"key":"10.1016\/j.ejps.2021.105940_bib0030","unstructured":"US Food and Drug Administration, 2017. Benznidazole prescribing information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209570lbl.pdf."},{"key":"10.1016\/j.ejps.2021.105940_bib0031","unstructured":"US Food and Drug Administration, 2020. Nifurtimox prescribing information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213464s000lbl.pdf."},{"key":"10.1016\/j.ejps.2021.105940_bib0032","unstructured":"US Pharmacopeial Convention, 2011. Uniformity of dosage units. Stage 6, Harmonization. December 01. Available from: https:\/\/www.usp.org\/sites\/default\/files\/usp\/document\/harmonization\/gen-method\/q0304_stage_6_monograph_25_feb_2011.pdf."},{"key":"10.1016\/j.ejps.2021.105940_bib0033","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0939-6411(01)00228-4","article-title":"2002. Breaking of scored tablets: a review","volume":"53","author":"van Santen","year":"2002","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2021.105940_bib0034","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1073\/pnas.0711014105","article-title":"A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes","volume":"105","author":"Wilkinson","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"10.1016\/j.ejps.2021.105940_bib0035","unstructured":"World Health Organization, 2002. Control of Chagas Disease \u2013 Second Report of the WHO Expert Committee, WHO Technical Report Series; 905, Geneva. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/42443."},{"key":"10.1016\/j.ejps.2021.105940_bib0036","unstructured":"World Health Organization, 2020. Chagas disease (American trypanosomiasis). Epidemiology. Available from: https:\/\/www.who.int\/health-topics\/chagas-disease#tab=tab_1."},{"key":"10.1016\/j.ejps.2021.105940_bib0037","unstructured":"World Health Organization, 2019. WHO model list of essential medicines \u201321st list. Available from: https:\/\/www.who.int\/publications\/i\/item\/WHOMVPEMPIAU2019.06."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721002438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721002438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:59:14Z","timestamp":1760529554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098721002438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":37,"alternative-id":["S0928098721002438"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2021.105940","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical investigation of the biopharmaceutical characteristics of nifurtimox tablets \u2013 Implications for quality control and application","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2021.105940","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105940"}}